Recombinant Mouse CGA protein (rFc Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3094

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse Cga was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse CGA protein Leu25-Tyr116 (Accession# P01216) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 12640
• Accession: P01216
• PredictedSize: 36.2 kDa
• SDS-PAGE: 40-50 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CGA (Chromogranin A), known as Chromogranin A, is an acidic, hydrophilic protein consisting of 439 amino acids with a molecular mass of approximately 48 kDa. It is a member of the neuropeptide family and is widely distributed in the neuroendocrine system. CGA has been an attractive therapeutic target and candidate biomarker for a variety of cardiovascular, neurological, and inflammatory diseases. CgA concentration is used as a diagnostic marker in hypertensive pheochromocytoma patients. (PMID: 36902417) Plasma CGA levels are diagnostic in prostate cancer and are particularly important in the monitoring and diagnosis of prostate-specific antigen-negative or progressive prostate cancer with distant metastases.

References:

1. Bralewska M, et al. Int J Mol Sci. 2023;24(5):4986.                                                 
2. Ploussard G, et al. World J Urol. 2023;41(2):361-369.                                              
3. Laguerre F,et al. IUBMB Life. 2020;72(4):524-532.                                                      
4. Iyer DR, et al. Cell Mol Life Sci. 2023;80(9):271.